Dr Bradley Noel Greenhaw, MD | |
516 Pegram Dr, Tupelo, MS 38801-6347 | |
(662) 844-6272 | |
(662) 844-1603 |
Full Name | Dr Bradley Noel Greenhaw |
---|---|
Gender | Male |
Speciality | Dermatology |
Experience | 14 Years |
Location | 516 Pegram Dr, Tupelo, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1215249131 | NPI | - | NPPES |
T-2318 | Other | MS | TEMPORART MS MEDICAL LICENSE NUMBER |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Dermatology Center Of North Ms Pa | 7416006986 | 5 |
News Archive
Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).
A mother's prolonged use of antibacterial soaps containing the chemical triclocarban may harm nursing babies, according to a recent study from the University of Tennessee, Knoxville.
A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers from the University of Illinois at Chicago show in a new study published in the Dec. 9 issue of Cancer Cell.
The National Cancer Institute has awarded the Arizona Cancer Center at the University of Arizona Health Sciences Center a three-year grant to evaluate associations between elevated arsenic exposure and cancer incidence in Arizona and Mexico.
› Verified 2 days ago
Entity Name | Dermatology Center Of North Ms Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1053491605 PECOS PAC ID: 7416006986 Enrollment ID: O20090513000267 |
News Archive
Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).
A mother's prolonged use of antibacterial soaps containing the chemical triclocarban may harm nursing babies, according to a recent study from the University of Tennessee, Knoxville.
A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers from the University of Illinois at Chicago show in a new study published in the Dec. 9 issue of Cancer Cell.
The National Cancer Institute has awarded the Arizona Cancer Center at the University of Arizona Health Sciences Center a three-year grant to evaluate associations between elevated arsenic exposure and cancer incidence in Arizona and Mexico.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Bradley Noel Greenhaw, MD 516 Pegram Dr, Tupelo, MS 38801-6347 Ph: (662) 844-6272 | Dr Bradley Noel Greenhaw, MD 516 Pegram Dr, Tupelo, MS 38801-6347 Ph: (662) 844-6272 |
News Archive
Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).
A mother's prolonged use of antibacterial soaps containing the chemical triclocarban may harm nursing babies, according to a recent study from the University of Tennessee, Knoxville.
A protein that shields tumor cells from cell death and exerts resistance to chemotherapy has an Achilles heel, a vulnerability that can be exploited to target and kill the very tumor cells it usually protects, researchers from the University of Illinois at Chicago show in a new study published in the Dec. 9 issue of Cancer Cell.
The National Cancer Institute has awarded the Arizona Cancer Center at the University of Arizona Health Sciences Center a three-year grant to evaluate associations between elevated arsenic exposure and cancer incidence in Arizona and Mexico.
› Verified 2 days ago
Dr. John D Burk, MD Dermatology Medicare: Medicare Enrolled Practice Location: 516 Pegram Dr, Tupelo, MS 38801 Phone: 662-844-6272 Fax: 662-844-1603 | |
Dr. Jeffrey C Houin, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 516 Pegram Dr, Tupelo, MS 38801 Phone: 662-844-6272 Fax: 662-844-1603 |